Actively Recruiting

Phase 1
Age: 19Years - 55Years
All Genders
Healthy Volunteers
NCT07570082

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

Led by Crinetics Pharmaceuticals Inc. · Updated on 2026-05-06

46

Participants Needed

1

Research Sites

34 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.

CONDITIONS

Official Title

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

Who Can Participate

Age: 19Years - 55Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthy adult males or females of non-childbearing potential aged 19-55 years at screening
  • Body mass index (BMI) between 18.0 and 32.0 kg/m2 at screening
  • Willing and able to follow all study procedures, restrictions, fasting, standardized meals, inpatient admission, follow-up, and abstain from tobacco, alcohol, drugs, and strenuous exercise during the study
  • Normal ACTH-stimulated cortisol test at screening without signs of adrenal insufficiency as judged by the investigator
Not Eligible

You will not qualify if you...

  • Mentally or legally incapacitated or with significant emotional problems at screening or expected during the study
  • History or presence of clinically significant medical or psychiatric conditions as judged by the investigator
  • Female participants with a positive pregnancy test at screening or first check-in or who are lactating
  • Female participants of childbearing potential
  • Previous treatment with atumelnant
  • Participation in another clinical study within 30 days or receipt of any investigational drug within 5 half-lives before first dosing
  • History or presence of hypersensitivity or idiosyncratic reaction to study drugs or related compounds
  • Blood loss of 500 mL or more or blood donation within 3 months prior to first dosing
  • Unable to avoid or expect to use any drugs, supplements, or herbal remedies within 14 days or 5 half-lives prior to first dosing

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Crinetics Study Site

Lincoln, Nebraska, United States, 68502

Actively Recruiting

Loading map...

Research Team

C

Crinetics Clinical Trials

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Drug-Drug Interaction Study of Atumelnant in Healthy Participants | DecenTrialz